P3 Health Partners (PIII) Stock Price, News & Analysis

Company Overview

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics. By combining proprietary software with professional services teams, P3 Health Partners assists payers in identifying gaps in care, enhancing member engagement and ensuring compliance with state and federal guidelines. Its solutions encompass data ingestion, normalization, predictive modeling and targeted outreach strategies designed to drive measurable improvements in clinical and financial outcomes.

Headquartered in Dallas, Texas, P3 Health Partners serves a broad base of commercial, Medicare Advantage and Medicaid health plans across the United States. The company is led by a management team with deep expertise in healthcare analytics, payer operations and quality improvement initiatives. Through strategic partnerships and ongoing investment in its technology platform, P3 Health Partners aims to help clients navigate the evolving healthcare landscape and deliver more cost-effective, member-centric care.

Key Stats

• Today's Range: $8.90 to $9.26
• 50-Day Range: $5.80 to $9.09
• 52-Week Range: $5.80 to $26.00
• Volume: 6,525 shs
• Average Volume: 8,202 shs
• Market Capitalization: $65.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.25
• Consensus Rating: Moderate Buy

P3 Health Partners Stock Analysis - MarketRank™

P3 Health Partners scored higher than 43% of companies evaluated by MarketBeat, and ranked 470th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

P3 Health Partners has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

P3 Health Partners has a consensus price target of $16.25, representing about 78.8% upside from its current price of $9.09.

Amount of Analyst Coverage

P3 Health Partners has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for P3 Health Partners are expected to grow in the coming year, from ($0.67) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of P3 Health Partners is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of P3 Health Partners is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

P3 Health Partners has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.36% of the float of P3 Health Partners has been sold short.

Short Interest Ratio / Days to Cover

P3 Health Partners has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in P3 Health Partners has recently increased by 0.80%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

P3 Health Partners does not currently pay a dividend.

Dividend Growth

P3 Health Partners does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.36% of the float of P3 Health Partners has been sold short.

Short Interest Ratio / Days to Cover

P3 Health Partners has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in P3 Health Partners has recently increased by 0.80%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for P3 Health Partners this week, compared to 1 article on an average week.

Search Interest

4 people have searched for PIII on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added P3 Health Partners to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, P3 Health Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.79% of the stock of P3 Health Partners is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.75% of the stock of P3 Health Partners is held by institutions.

PIII Stock Analysis - Frequently Asked Questions

How have PIII shares performed this year?

P3 Health Partners' stock was trading at $11.2450 at the beginning of 2025. Since then, PIII stock has decreased by 19.2% and is now trading at $9.09.

How were P3 Health Partners' earnings last quarter?

P3 Health Partners Inc. (NASDAQ:PIII) posted its earnings results on Thursday, August, 14th. The company reported ($6.23) earnings per share for the quarter, missing the consensus estimate of ($3.29) by $2.94. The company earned $355.79 million during the quarter, compared to the consensus estimate of $356.52 million. P3 Health Partners had a negative net margin of 9.99% and a negative trailing twelve-month return on equity of 183.60%.
Read the conference call transcript.

When did P3 Health Partners' stock split?

P3 Health Partners's stock reverse split on Monday, April 14th 2025.The 1-50 reverse split was announced on Friday, April 4th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Who are P3 Health Partners' major shareholders?

P3 Health Partners' top institutional shareholders include Corient Private Wealth LLC (0.49%), Trinity Financial Advisors LLC (0.35%) and Geode Capital Management LLC (0.28%). Insiders that own company stock include Pacific Founders Ugp Chicago, Pacific Founders Ugp I Chicago, Sherif Abdou and Atul Kavthekar.
View institutional ownership trends.

How do I buy shares of P3 Health Partners?

Shares of PIII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of P3 Health Partners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that P3 Health Partners investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), TriNet Group (TNET), Taiwan Semiconductor Manufacturing (TSM), XPeng (XPEV), 3M (MMM) and nCino (NCNO).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/24/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PIII
• CIK: 1832511
• Web: foresightacq.com
• Phone: 702-910-3950
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Price Target for P3 Health Partners: $16.25
• High Price Target: $20.00
• Low Price Target: $12.50
• Potential Upside/Downside: +78.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($46.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$135.85 million
• Net Margins: -9.99%
• Pretax Margin: -21.58%
• Return on Equity: -183.60%
• Return on Assets: -17.83%

Debt

• Debt-to-Equity Ratio: 2.29
• Current Ratio: 0.31
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $1.46 billion
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.58 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 7,187,000
• Free Float: 5,908,000
• Market Cap: $65.33 million
• Optionable: Not Optionable
• Beta: 0.82